| Literature DB >> 20425387 |
Abstract
Polycythemia vera is a myeloproliferative disease, which, if untreated, leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis, anemia, and splenomegaly. Two newly available drugs, interferon alfa and imatinib mesylate, may alter the course of this disease. Used as single agents, each produces lasting remissions in about 75% of patients with polycythemia vera. Of significance, change in JAK2 expression has been reported after treatment with both agents.Entities:
Mesh：
Substances：
Year: 2007 PMID： 20425387 DOI： 10.1007/s11899-007-0006-2
Source DB: PubMed Journal: Curr Hematol Malig Rep ISSN： 1558-8211 Impact factor: 4.213